迪瑞醫療(300396.SZ)擬3000萬元成立30家全資子公司
格隆匯5月25日丨迪瑞醫療(300396.SZ)公佈,為了抓住國家優化基層醫療建設的機遇,深耕細分市場,滿足公司快速發展需要,進一步強化和完善分銷體系,擬在全國範圍內成立預計30家全資子公司,每家子公司註冊資本100萬元,預計總投資額3000萬元。
成立子公司目的是在深化落實公司產品分產線營銷管理前提下,進一步推進與渠道商深度合作,打造利益共同體,實現區域人員本土化管理,做細、做大、做強區域產品市場,助力公司快速發展。
公司本着自主研發實現儀器和試劑均衡發展,目前涉及尿液分析、生化分析、血液分析,化學發光免疫分析,婦科汾泌物分析,凝血分析、整體化實驗室等七大產品體系,先後推出的全自動尿液分析系統、模塊化生化免疫分析系統去人工化,最大限度提高生物安全性等自動化檢測產品得到了市場的認可。為了抓住國家醫學中心、區域醫療中心等基地建設的機會。積極參與疾控機構與城鄉社區聯動工作當中。同時,在全國範圍設立子公司也會加強與當地經銷商的溝通聯絡,增加多種合作方式夯實分銷體系,培養當地售服人員,最大化提高服務管理水平,對公司具有積極的戰略意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.